Placebo News and Research

RSS

Clazosentan reduces risk of blood vessel spasm in patients with brain aneurysm

An experimental drug, clazosentan, reduced the risk of blood vessel spasm in patients with a brain aneurysm, according to research presented at the American Stroke Association's International Stroke Conference 2012.

1 Feb 2012

Cystic fibrosis drug gets FDA approval

A drug – the first of its kind - that treats the root cause of cystic fibrosis won approval Tuesday. This could be a ray of hope for patients with the deadly illness and broader hope for thousands more patients with the inherited disease.

1 Feb 2012

Continuous wound infusion with local anesthetic reduces pain after hip surgery

In patients undergoing hip replacement surgery, using a special wound catheter to infuse local anesthetic directly into the hip joint provides significant and lasting improvements in postoperative pain control, reports a study in the February issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

1 Feb 2012

Vertex receives FDA approval for Kalydeco to treat rare form of CF

The U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.

1 Feb 2012

Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.

31 Jan 2012

ESC welcomes 'intriguing' study on heart failure

The European Society of Cardiology (ESC) welcomes an "intriguing" study, published today in the Journal of the American College of Cardiology, featuring a completely novel approach for improving endothelial function in heart failure.

31 Jan 2012

Juventas' JVS-100 Phase I heart failure trial meets primary safety endpoint

Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease. The Company's lead product, JVS-100, encodes Stromal cell-Derived Factor 1 (SDF-1) which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of blood flow.

31 Jan 2012

Array second quarter revenue increases to $23.2 million

Array BioPharma Inc. today reported financial results for the second quarter of fiscal 2012.

31 Jan 2012

AMAG completes enrollment in Feraheme Phase III program for iron-deficiency anemia

AMAG Pharmaceuticals, Inc. today announced the completion of patient enrollment in the second of the company's two phase III studies that comprise its global registrational program for Feraheme (ferumoxytol) in patients with iron-deficiency anemia (IDA) who are not candidates for oral iron, regardless of the underlying cause.

30 Jan 2012

Tea could help lower high blood pressure: Study

The study shows that people who drank three cups of black tea a day were able to lower their blood pressure. This was seen when compared to those who drank a placebo similar in taste and caffeine content. Those who drank the tea saw a slight drop in both systolic and diastolic blood pressure over six months.

29 Jan 2012

Two NIH clinical trials to evaluate treatments for out-of-hospital cardiac arrest

The National Institutes of Health has launched two multi-site clinical trials to evaluate treatments for out-of-hospital cardiac arrest. One will compare continuous chest compressions (CCC) combined with pause- free rescue breathing to standard cardiopulmonary resuscitation (CPR), which includes a combination of chest compressions and pauses for rescue breathing.

27 Jan 2012

Boehringer Ingelheim initiates two afatinib phase III trials in head and neck cancer

Boehringer Ingelheim announced today the initiation of two phase III clinical trials, LUX-Head & Neck 1 and LUX-Head & Neck 2. These trials evaluate afatinib in patients with metastatic and recurrent head and neck cancer, and in patients with locally advanced disease, respectively.

27 Jan 2012

LEO Pharma receives FDA approval for Picato topical gel to treat AK

LEO Pharma announced today that the U.S. Food and Drug Administration (FDA) approved Picato (ingenol mebutate) gel (0.015%, 0.05%) for the topical treatment of actinic keratosis.

27 Jan 2012

FDA approves UCB's Keppra for treatment of partial onset seizures in infants

UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Keppra (levetiracetam) tablets and oral solution as adjunctive therapy in the treatment of partial onset seizures in adults and children one month of age and older with epilepsy.

27 Jan 2012

Amorcyte commences enrollment in PreSERVE Phase 2 trial for acute myocardial infarction

Amorcyte, LLC, a NeoStem, Inc. company today announces the enrollment of the first patient in the Amorcyte PreSERVE Phase 2 trial for acute myocardial infarction.

25 Jan 2012

Lansoprazole increases risk of sore throats, respiratory problems in children with asthma

Adding the acid reflux drug lansoprazole to a standard inhaled steroid treatment for asthma does not improve asthma control in children who have no symptom of acid reflux, according to a new study funded in part by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. Lansoprazole therapy slightly increased the risk of sore throats and other respiratory problems in children, however.

25 Jan 2012

Lansoprazole does not control asthma in children

Asthma and gastroesophageal reflux (GER) are both common illnesses in children. GER in children often occurs without the typical symptoms of heartburn, and physicians frequently prescribe the acid reflux drug lansoprazole to supplement the standard inhaled steroid treatment for children with uncontrolled asthma regardless of GER symptoms.

25 Jan 2012

Cytori's ADRCs safe and feasible for patients with AMI

Cytori Therapeutics announced today the publication of previously reported six-month outcomes from APOLLO, the Company's European clinical trial evaluating adipose-derived stem and regenerative cells (ADRCs) in patients with acute myocardial infarction, as Research Correspondence in the Journal of the American College of Cardiology.

25 Jan 2012

Dutaseride may help prevent progression of early stage prostate cancer: Study

A new study suggests that men with early stage prostate cancer may benefit with drugs that can slow or stop the cancer’s progress. Less than 10 percent of the 100,000 men each year who are diagnosed with early-stage prostate cancer and have the option of leaving the cancer in place. Rest get it removed using surgery or radiation. But those treatments can have serious side effects like impotence and incontinence.

24 Jan 2012

Stem cells show promise in treating blindness

A medical breakthrough was reported Monday in the journal The Lancet wherein the results of a therapy using human embryonic stem cells in two legally blind patients was described.

24 Jan 2012